These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7127335)

  • 21. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etoposide as single agent and in combination with cis-platinum for malignant lymphomas.
    Kroner T; Obrecht JP; Jungi WF
    Cancer Treat Rev; 1982 Jun; 9 Suppl():39-43. PubMed ID: 6889920
    [No Abstract]   [Full Text] [Related]  

  • 23. A review of etoposide in patients with non-small-cell lung cancer (NSCLC).
    Itri LM; Gralla RJ
    Cancer Treat Rev; 1982 Jun; 9 Suppl():115-8. PubMed ID: 6889916
    [No Abstract]   [Full Text] [Related]  

  • 24. [Phase II study of etoposide in patients with lung cancer, with special reference to small cell carcinoma].
    Kurita Y; Yokoyama A; Kinameri K; Matsuura N; Sano K
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):108-11. PubMed ID: 3009665
    [No Abstract]   [Full Text] [Related]  

  • 25. Etoposide--an effective single drug for treating bronchogenic carcinoma.
    Anderson G; Peel ET; Cheong CM; Broderick NJ
    Clin Oncol; 1982; 8(3):215-8. PubMed ID: 7140048
    [No Abstract]   [Full Text] [Related]  

  • 26. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 27. [The treatment of acute myelocytic leukemia during the first recurrence by means of a new cytostatic combination].
    Cavalli F; Sauter C; Senn HJ; Alberto P
    Schweiz Med Wochenschr; 1976 Sep; 106(38):1265-8. PubMed ID: 1070154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma.
    Goldhirsch A; Joss R; Cavalli F; Brunner KW
    Cancer Treat Rev; 1982 Jun; 9 Suppl():85-90. PubMed ID: 6290057
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment strategies in relation to drug action.
    Muggia FM; McVie G
    NCI Monogr; 1987; (4):129-33. PubMed ID: 2819724
    [No Abstract]   [Full Text] [Related]  

  • 30. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.
    Cavalli F; Sonntag RW; Jungi F; Senn HJ; Brunner KW
    Cancer Treat Rep; 1978 Mar; 62(3):473-5. PubMed ID: 348319
    [No Abstract]   [Full Text] [Related]  

  • 31. Review of etoposide.
    Phillips NC; Lauper RD
    Clin Pharm; 1983; 2(2):112-9. PubMed ID: 6309469
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 33. Etoposide alone and in combination with cyclophosphamide, adriamycin and cis-platinum in patients with Mo and Mi non-small-cell lung cancer.
    Eagan RT
    Cancer Treat Rev; 1982 Jun; 9 Suppl():119-31. PubMed ID: 6889917
    [No Abstract]   [Full Text] [Related]  

  • 34. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent.
    Sinkule JA
    Pharmacotherapy; 1984; 4(2):61-73. PubMed ID: 6326063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etoposide and cisplatin salvage chemotherapy for small cell lung cancer.
    Lopez JA; Mann J; Grapski RT; Nassif E; Vannicola P; Krikorian JG; Finkel H
    Cancer Treat Rep; 1985 Apr; 69(4):369-71. PubMed ID: 2986833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.
    Chard RL; Krivit W; Bleyer WA; Hammond D
    Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of anaplastic carcinoma of the lung with VP 16-213].
    Sanz Ortíz J; Saiz García F
    Med Clin (Barc); 1982 Oct 16-31; 79(7):322-4. PubMed ID: 6294420
    [No Abstract]   [Full Text] [Related]  

  • 38. Etoposide for therapy-resistant testicular tumors.
    Varini M; Cavalli F
    Cancer Treat Rev; 1982 Jun; 9 Suppl():73-8. PubMed ID: 7127337
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of etoposide for urogenital tumors].
    Kinjo T; Murase T; Aota Y; Shimoji T; Mitsuya H
    Gan To Kagaku Ryoho; 1985 Jun; 12(6):1267-71. PubMed ID: 4004290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Phase II study of VP-16 in patients with primary bronchogenic carcinoma, with special reference to small cell carcinoma--a multi-institutional cooperative study].
    Kanda T; Oka M; Hara K; Koteda T; Ishizaki T; Ikebe A; Nakano M; Iwasaki H; Tsutsumi T; Okuno K
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):12-8. PubMed ID: 3009666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.